What is Remedy Plan?
Remedy Plan Therapeutics operates at the intersection of oncology and metabolic research, specializing in the development of small molecule inhibitors targeting NAMPT. The company has pioneered a unique, tunable mechanism that addresses the critical challenge of on-target toxicity, a common hurdle in previous NAMPT-focused therapeutic efforts. By modulating this pathway with high precision, Remedy Plan is developing a robust pipeline aimed at addressing significant unmet medical needs, including solid tumors, hematologic malignancies, obesity, and various autoimmune disorders.
The company's market position is defined by its ability to unlock therapeutic opportunities previously considered inaccessible due to safety concerns. Through its innovative platform, Remedy Plan is effectively bridging the gap between fundamental biological research and clinical application, positioning itself as a key player in the next generation of targeted molecular therapies.
How much funding has Remedy Plan raised?
Remedy Plan has raised a total of $18M across 1 funding round:
Other Financing Round
$18M
Other Financing Round (2025): $18M with participation from Schooner Capital and Alexandria Venture Investments LLC Alexandria Venture Investments
Key Investors in Remedy Plan
Schooner Capital
Schooner Capital is an established investment firm that focuses on fostering long-term growth and providing strategic guidance to entrepreneurs and companies seeking to achieve their financial and operational goals.
Alexandria Venture Investments LLC
Alexandria Venture Investments LLC is a specialized venture capital firm that focuses on identifying and supporting high-potential companies within the private equity and biotechnology sectors.
What's next for Remedy Plan?
With the recent influx of capital, Remedy Plan is poised to scale its research and development operations significantly. The strategic roadmap focuses on advancing its lead candidates through preclinical validation and toward initial human trials. By leveraging the expertise of its financial partners, the company intends to refine its tunable inhibition platform, potentially expanding its therapeutic reach into additional indications where NAMPT dysregulation plays a central role.
The focus remains on maintaining a lean, high-impact operational model while aggressively pursuing regulatory milestones. As the company matures, the emphasis will likely shift toward strategic partnerships or licensing agreements that can further validate its technology and provide the necessary infrastructure for large-scale clinical trials. This phase of growth is critical for establishing Remedy Plan as a leader in the small molecule therapeutics sector.
